Evaluation of [11C]MRB for assessment of occupancy of norepinephrine transporters: Studies with atomoxetine in non-human primates

NeuroImage

Volumn 56, Issue 1, 2011, Pages 268-279

  Gallezot, Jean Dominique ^a   Weinzimmer, David ^a   Nabulsi, Nabeel ^a   Lin, Shu Fei ^a   Fowles, Krista ^a   Sandiego, Christine ^a   McCarthy, Timothy J ^b   Maguire, R Paul ^b   Carson, Richard E ^a   Ding, Yu Shin ^a  

^a YALE UNIVERSITY   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLREBOXETINE C 11; ATOMOXETINE; NORADRENALIN TRANSPORTER; PLACEBO; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; BRAIN REGION; CAUDATE NUCLEUS; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG PROTEIN BINDING; IC 50; LOW DRUG DOSE; NONHUMAN; OCCIPITAL CORTEX; POSITRON EMISSION TOMOGRAPHY; PRIMATE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PUTAMEN; RHESUS MONKEY; THALAMUS;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; BRAIN; CARBON RADIOISOTOPES; MACACA MULATTA; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; POSITRON-EMISSION TOMOGRAPHY; PROPYLAMINES; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 79953045711     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2010.09.040     Document Type: Article

References (44)

1. Arakawa R., Okumura M., Ito H., Seki C., Takahashi H., Takano H., Nakao R., Suzuki K., Okubo Y., Halldin C., Suhara T. Quantitative analysis of norepinephrine transporter in the human brain using PET with (S, S)-18F-FMeNER-D2. J. Nucl. Med. 2008, 49:1270-1276.
2. Barker E.L., Blakely R.D. Norepinephrine and serotonin transporters: molecular targets of antidepressant drugs. Psychopharmacology: the fourth generation of progress 1995, 321-334. Raven Press, New York, NY. F.E. Bloom, D.J. Kupfer (Eds.).
3. Beck J., Arnold K. Parameter estimation in engineering and science 1977, Wiley, New York, NY.
4. Bymaster F.P., Katner J.S., Nelson D.L., Hemrick-Luecke S.K., Threlkeld P.G., Heiligenstein J.H., Morin S.M., Gehlert D.R., Perry K.W. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002, 27:699-711.
5. Carson R.E., Barker W.C., Liow J., Johnson C.A. Design of a motion-compensation OSEM list-mode algorithm for resolution-recovery reconstruction for the HRRT. IEEE Nucl. Sci. Symp. Conf. Rec. 2003, 5:3281-3285.
6. Cunningham V.J., Rabiner E., Slifstein M., Laruelle M., Gunn R.N. Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J. Cereb. Blood Flow Metab. 2010, 30:46-50.
7. Ding Y.S., Lin K.S., Garza V., Carter P., Alexoff D., Logan J., Shea C., Xu Y., King P. Evaluation of a new norepinephrine transporter PET ligand in baboons, both in brain and peripheral organs. Synapse 2003, 50:345-352.
8. Ding Y.S., Lin K.S., Logan J., Benveniste H., Carter P. Comparative evaluation of positron emission tomography radiotracers for imaging the norepinephrine transporter: (S, S) and (R, R) enantiomers of reboxetine analogs ([11C]methylreboxetine, 3-Cl-[11C]methylreboxetine and [18F]fluororeboxetine), (R)-[11C]nisoxetine, [11C]oxaprotiline and [11C]lortalamine. J. Neurochem. 2005, 94:337-351.
9. Ding Y.S., Lin K.S., Logan J. PET imaging of norepinephrine transporters. Curr. Pharm. Des. 2006, 12:3831-3845.
10. Ding Y.S., Singhal T., Planeta-Wilson B., Gallezot J.D., Nabulsi N., Labaree D., Ropchan J., Henry S., Williams W., Carson R.E., Neumeister A., Malison R.T. PET imaging of the effects of age and cocaine on the norepinephrine transporter in the human brain using (S,S)-[(11)C]O-methylreboxetine and HRRT. Synapse 2010, 64:30-38.
11. Gallezot J.D., Planeta-Wilson B., Wang G.J., Carson R.E., Ding Y.S. Kinetic modeling of the net radioligand [C-11]MRB in humans: a test-retest study. J. Cereb. Blood Flow Metab. 2007, 27. Suppl 1, 23.
12. Hannestad J., Gallezot J.-D., Planeta-Wilson B., Lin S.-F., Williams W.A., van Dyck C.H., Malison R.T., Carson R.E., Ding Y.S. Clinically relevant doses of dethylphenidate significantly occupy norepinephrine transporters in humans in vivo. Biol Psychiatry 2010, 68:854-860.
13. Hoogendijk W.J., Pool C.W., Troost D., van Zwieten E., Swaab D.F. Image analyser-assisted morphometry of the locus coeruleus in Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. Brain 1995, 118:131-143.
14. Ichise M., Ballinger J.R., Golan H., Vines D., Luong A., Tsai S., Kung H.F. Noninvasive quantification of dopamine D2 receptors with iodine-123-IBF SPECT. J. Nucl. Med. 1996, 37:513-520.
15. Ichise M., Toyama H., Innis R.B., Carson R.E. Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J. Cereb. Blood Flow Metab. 2002, 22:1271-1281.
16. Ichise M., Liow J.S., Lu J.Q., Takano A., Model K., Toyama H., Suhara T., Suzuki K., Innis R.B., Carson R.E. Linearized reference tissue parametric imaging methods: Application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J. Cereb. Blood Flow Metab. 2003, 23:1096-1112.
17. Innis R.B., Cunningham V.J., Delforge J., Fujita M., Gjedde A., Gunn R.N., Holden J., Houle S., Huang S.C., Ichise M., Iida H., Ito H., Kimura Y., Koeppe R.A., Knudsen G.M., Knuuti J., Lammertsma A.A., Laruelle M., Logan J., Maguire R.P., Mintun M.A., Morris E.D., Parsey R., Price J.C., Slifstein M., Sossi V., Suhara T., Votaw J.R., Wong D.F., Carson R.E. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab. 2007, 27:1533-1539.
18. Johnson C.A., Thada S., Rodriguez M., Zhao Y., Iano-Fletcher A.R., Liow J., Barker W.C., Martino R.L., Carson R.E. Software architecture of the MOLAR-HRRT reconstruction engine. IEEE Nucl. Sci. Symp. Conf. Rec. 2004, 6:3956-3960.
19. Kaufman M.J., Spealman R.D., Madras B.K. Distribution of cocaine recognition sites in monkey brain: I. In vitro autoradiography with [3H]CFT. Synapse 1991, 9:177-187.
20. Kielbasa W., Kalvass J.C., Stratford R. Microdialysis evaluation of atomoxetine brain penetration and central nervous system pharmacokinetics in rats. Drug Metab. Dispos. 2009, 37:137-142.
21. Lin K.S., Ding Y.S. Synthesis, enantiomeric resolution, and selective C-11 methylation of a highly selective radioligand for imaging the norepinephrine transporter with positron emission tomography. Chirality 2004, 16:475-481.
22. Lin K.S., Ding Y.S., Kim S.W., Kil K.E. Synthesis, enantiomeric resolution, F-18 labeling and biodistribution of reboxetine analogs: promising radioligands for imaging the norepinephrine transporter with Positron Emission Tomography. Nucl. Med. Biol. 2005, 32:415-422.
23. Lassen N.A., Bartenstein P.A., Lammertsma A.A., Prevett M.C., Turton D.R., Luthra S.K., Osman S., Bloomfield P.M., Jones T., Patsalos P.N. Benzodiazepine receptor quantification in vivo in humans using [11C]flumazenil and PET: application of the steady-state principle. J. Cereb. Blood Flow Metab. 1995, 15:152-165.
24. Logan J., Fowler J.S., Volkow N.D., Wolf A., Dewey S.L., Schlyer D., Macgregor R., Hitzemann Bendriem, Gatley S., Christman D. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C -methyl]-(-)-cocaine PET studies in human subjects. J. Cereb. Blood Flow Metab. 1990, 10:740-747.
25. Logan J., Ding Y.S., Lin K.S., Pareto D., Fowler J.S., Biegon A. Modeling and analysis of PET studies with norepinephrine transporter ligands: The search for a reference region. Nucl. Med. Biol. 2005, 32:531-542.
26. Logan J., Wang G.J., Telang F., Fowler J.S., Alexoff D., Zabroski J., Jayne M., Hubbard B., King P., Carter P., Shea C., Xu Y., Muench L., Schlyer D., Learned-Coughlin S., Cosson V., Volkow N.D., Ding Y.S. Imaging the norepinephrine transporter in humans with (S, S)-[ 11C]O-methyl reboxetine and PET: Problems and progress. Nucl. Med. Biol. 2007, 34:667-679.
27. Marquardt D. An algorithm for least square estimation of nonlinear parameters. SIAM J. Appl. Math. 1963, 11:431-441.
28. Mattiuz E.L., Ponsler G.D., Barbuch R.J., Wood P.G., Mullen J.H., Shugert R.L., Li Q., Wheeler W.J., Kuo F., Conrad P.C., Sauer J.M. Disposition and metabolic fate of atomoxetine hydrochloride: Pharmacokinetics, metabolism, and excretion in the Fischer 344 rat and beagle dog. Drug Metab. Dispos. 2003, 31:88-97.
29. Melloni P.C.G., Della Torre A., Bonsignori A., Buonamici M., Pozzi O.R.S., Rossi A.C. Potential antidepressant agents. A-aryloxy-benzyl derivatives of ethanolamine and morpholine. Eur. J. Med. Chem. 1984, 19:235-242.
30. Morón J.A., Brockington A., Wise R.A., Rocha B.A., Hope B.T. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: Evidence from knock-out mouse lines. J. Neurosci. 2002, 22:389-395.
31. Nabulsi N., Huang Y., Weinzimmer D., Ropchan J., Frost J.J., McCarthy T., Carson R.E., Ding Y.S. High-resolution imaging of brain 5-HT1B receptors in the rhesus monkey using [11C]P943. Nucl. Med. Biol. 2010, 37:205-214.
32. Sauer J., Ponsler G.D., Mattiuz E.L., Long A.J., Witcher J.W., Thomasson H.R., Desante K.A. Disposition and metabolic fate of atomoxetine hydrochloride: The role of CYP2D6 in human disposition and metabolism. Drug Metab. Dispos. 2003, 31:98-107.
33. Schou M., Halldin C., Sóvágó J., Pike V.W., Gulyás B., Mozley P.D., Johnson D.P., Hall H., Innis R.B., Farde L. Specific in vivo binding to the norepinephrine transporter demonstrated with the PET radioligand, (S, S)-[ 11C]MeNER. Nucl. Med. Biol. 2003, 30:707-714.
34. Schou M., Halldin C., Sóvágó J., Pike V.W., Hall H., Gulyás B., Mozley P.D., Dobson D., Shchukin E., Innis R.B., Farde L. PET evaluation of novel radiofluorinated reboxetine analogs as norepinephrine transporter probes in the monkey brain. Synapse 2004, 53:57-67.
35. Schou M., Halldin C., Pike V.W., Mozley P.D., Dobson D., Innis R.B., Farde L., Hall H. Post-mortem human brain autoradiography of the norepinephrine transporter using (S, S)-[18F]FMeNER-D2. Eur. Neuropsychopharmacol. 2005, 15:517-520.
36. Seneca N., Gulyás B., Varrone A., Schou M., Airaksinen A., Tauscher J., Vandenhende F., Kielbasa W., Farde L., Innis R.B., Halldin C. Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: A PET study in nonhuman primate brain using (S, S)-[18F]FMeNER-D2. Psychopharmacology (Berl) 2006, 188:119-127.
37. Smith H.R., Beveridge T.J., Porrino L.J. Distribution of norepinephrine transporters in the non-human primate brain. Neuroscience 2006, 138:703-714.
38. Spencer T.J., Biederman J., Wilens T.E., Faraone S.V. Novel treatments for attention-deficit/hyperactivity disorder in children. J. Clin. Psychiatry 2002, 63(Suppl 12):16-22.
39. Takano A., Gulyás B., Varrone A., Maguire R.P., Halldin C. Saturated norepinephrine transporter occupancy by atomoxetine relevant to clinical doses: a rhesus monkey study with (S, S)-[(18)F]FMeNER-D(2). Eur. J. Nucl. Med. 2009, 36:1308-1314.
40. Takano A., Gulyás B., Varrone A., Halldin C. Comparative evaluations of norepinephrine transporter radioligands with reference tissue models in rhesus monkeys: (S, S)-[(18)F]FMeNER-D(2) and (S, S)-[(11)C]MeNER. Eur. J. Nucl. Med. 2009, 36:1892-1895.
41. Tatsumi M., Groshan K., Blakely R.D., Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur. J. Pharmacol. 1997, 340:249-258.
42. Wilson A.A., Johnson D.P., Mozley D., Hussey D., Ginovart N., Nobrega J., Garcia A., Meyer J., Houle S. Synthesis and in vivo evaluation of novel radiotracers for the in vivo imaging of the norepinephrine transporter. Nucl. Med. Biol. 2003, 30:85-92.
43. Wong D.T., Threlkeld P.G., Best K.L., Bymaster F.P. A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. J. Pharmacol. Exp. Ther. 1982, 222:61-65.
44. Zeng Z., Chen T.B., Miller P.J., Dean D., Tang Y.S., Sur C., Williams D.L. The serotonin transporter in rhesus monkey brain: Comparison of DASB and citalopram binding sites. Nucl. Med. Biol. 2006, 33:555-563.